Symbols / STOK
STOK Chart
About
Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, engages in the development of treatments for severe genetic diseases by upregulating protein expression. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO) approach in developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Its lead product candidates include STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy; and Zorevunersen (STK-001), an investigational new medicine for the treatment of Dravet syndrome is being evaluated in phase I/II clinical trials. The company also develops programs focused on various targets, including haploinsufficiency diseases of the central nervous system and eye. It has a license and collaboration with Biogen Inc. for the development and commercialization of zorevunersen medicine for the treatment of Dravet syndrome; and Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of genetic neurodevelopmental diseases. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 2.03B |
| Enterprise Value | 1.78B | Income | 40.57M | Sales | 205.63M |
| Book/sh | 5.59 | Cash/sh | 4.35 | Dividend Yield | — |
| Payout | 0.00% | Employees | 128 | IPO | — |
| P/E | 52.21 | Forward P/E | -11.38 | PEG | — |
| P/S | 9.86 | P/B | 6.35 | P/C | — |
| EV/EBITDA | 61.34 | EV/Sales | 8.68 | Quick Ratio | 6.21 |
| Current Ratio | 6.53 | Debt/Eq | 1.55 | LT Debt/Eq | — |
| EPS (ttm) | 0.68 | EPS next Y | -3.12 | EPS Growth | — |
| Revenue Growth | 117.20% | Earnings | 2026-03-24 | ROA | 5.20% |
| ROE | 15.02% | ROIC | — | Gross Margin | 100.00% |
| Oper. Margin | -4.05% | Profit Margin | 19.73% | Shs Outstand | 57.12M |
| Shs Float | 41.86M | Short Float | 23.47% | Short Ratio | 15.27 |
| Short Interest | — | 52W High | 38.69 | 52W Low | 5.35 |
| Beta | 1.11 | Avg Volume | 791.02K | Volume | 810.46K |
| Target Price | $41.70 | Recom | Strong_buy | Prev Close | $36.23 |
| Price | $35.50 | Change | -2.01% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$41.70
Mean price target
2. Current target
$35.50
Latest analyst target
3. DCF / Fair value
$9.32
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$35.50
Low
$35.00
High
$60.00
Mean
$41.70
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-02-24 | init | Wolfe Research | — → Outperform | $40 |
| 2026-01-12 | main | Wedbush | Outperform → Outperform | $36 |
| 2026-01-05 | main | Chardan Capital | Buy → Buy | $35 |
| 2026-01-05 | main | Canaccord Genuity | Buy → Buy | $36 |
| 2025-12-15 | main | HC Wainwright & Co. | Buy → Buy | $50 |
| 2025-11-05 | main | Canaccord Genuity | Buy → Buy | $28 |
| 2025-11-05 | main | Wedbush | Outperform → Outperform | $32 |
| 2025-11-05 | reit | BTIG | Buy → Buy | $39 |
| 2025-11-03 | main | JP Morgan | Neutral → Neutral | $25 |
| 2025-10-13 | main | BTIG | Buy → Buy | $39 |
| 2025-10-10 | main | Needham | Buy → Buy | $35 |
| 2025-08-13 | main | Chardan Capital | Buy → Buy | $24 |
| 2025-08-13 | main | Wedbush | Outperform → Outperform | $22 |
| 2025-07-18 | init | Jefferies | — → Buy | $30 |
| 2025-07-01 | reit | Needham | Buy → Buy | $22 |
| 2025-05-14 | main | HC Wainwright & Co. | Buy → Buy | $35 |
| 2025-04-09 | reit | Needham | Buy → Buy | $22 |
| 2025-03-19 | reit | HC Wainwright & Co. | Buy → Buy | $47 |
| 2025-03-19 | main | Chardan Capital | Buy → Buy | $24 |
| 2025-03-18 | reit | Needham | Buy → Buy | $22 |
- Stoke Therapeutics (NASDAQ:STOK) Upgraded to Strong-Buy at Wolfe Research - MarketBeat Wed, 25 Feb 2026 11
- $STOK stock is up 8% today. Here's what we see in our data. - Quiver Quantitative Mon, 23 Feb 2026 14
- A Look At Stoke Therapeutics (STOK) Valuation After Recent Share Price Momentum - Yahoo Finance ue, 24 Feb 2026 12
- First Week of STOK April 17th Options Trading - Nasdaq Mon, 23 Feb 2026 15
- Biotech CEO behind RNA Dravet drug joins TD Cowen conference lineup - Stock Titan ue, 24 Feb 2026 21
- Stoke Therapeutics stock swings premarket after Wolfe starts coverage with $40 target (STOK) - TechStock² ue, 24 Feb 2026 13
- Stoke Therapeutics (STOK) Is Up 13.5% After First Patient Dosed In STK-002 OSPREY Trial - simplywall.st ue, 24 Feb 2026 05
- Stoke Therapeutics, Inc. (STOK) Stock Analysis: Impressive Revenue Growth and Promising Upside - DirectorsTalk Interviews Fri, 20 Feb 2026 21
- Wolfe Research Initiates Coverage on Stoke Therapeutics (STOK) w - GuruFocus ue, 24 Feb 2026 13
- Forecasting The Future: 5 Analyst Projections For Stoke Therapeutics - Benzinga ue, 24 Feb 2026 13
- Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - Business Wire Wed, 18 Feb 2026 21
- Biotech Leader Stoke Therapeutics Offers Multiple Entries As Revenue Surges 117% - Investor's Business Daily ue, 16 Dec 2025 08
- With Stoke Therapeutics Stock Surging, Have You Considered The Downside? - Trefis Sat, 20 Dec 2025 08
- Wolfe Research Initiates Coverage of Stoke Therapeutics (STOK) with Outperform Recommendation - Nasdaq ue, 24 Feb 2026 13
- Wolfe Research Maintains Stoke Therapeutics(STOK.US) With Buy Rating, Raises Target Price to $40 - 富途牛牛 ue, 24 Feb 2026 15
Insider Transactions
| Date | Shares | Url | Text | Insider | Position | Transaction | Start Date | Ownership | Value |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 1211 | — | — | LEVIN ARTHUR A. | Director | — | 2025-12-31 00:00:00 | D | nan |
| 1 | 13430 | — | Sale at price 31.44 - 33.10 per share. | KAYE EDWARD M | Director | — | 2025-12-08 00:00:00 | D | 433385.0 |
| 2 | 3978 | — | Sale at price 31.60 - 32.61 per share. | ALLAN JONATHAN | General Counsel | — | 2025-12-08 00:00:00 | D | 128411.0 |
| 3 | 15001 | — | Sale at price 30.76 - 31.85 per share. | KAYE EDWARD M | Director | — | 2025-12-05 00:00:00 | D | 466959.0 |
| 4 | 5358 | — | Sale at price 30.76 - 31.35 per share. | TICHO BARUCH S | Officer | — | 2025-12-05 00:00:00 | D | 167115.0 |
| 5 | 9803 | — | Sale at price 30.76 - 31.76 per share. | ALLAN JONATHAN | General Counsel | — | 2025-12-05 00:00:00 | D | 306322.0 |
| 6 | 2136 | — | Sale at price 29.56 - 30.85 per share. | KAYE EDWARD M | Director | — | 2025-12-03 00:00:00 | D | 64541.0 |
| 7 | 26250 | — | — | KAYE EDWARD M | Director | — | 2025-12-03 00:00:00 | D | nan |
| 8 | 4020 | — | Sale at price 29.56 - 30.85 per share. | TICHO BARUCH S | Officer | — | 2025-12-03 00:00:00 | D | 121468.0 |
| 9 | 10000 | — | — | TICHO BARUCH S | Officer | — | 2025-12-03 00:00:00 | D | nan |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -99.19M | -112.30M | -102.81M | -85.09M |
| NetIncomeFromContinuingOperationNetMinorityInterest | -88.98M | -104.70M | -101.07M | -85.81M |
| ReconciledDepreciation | 2.18M | 2.47M | 1.55M | 974.00K |
| EBITDA | -99.19M | -112.30M | -102.81M | -85.09M |
| EBIT | -101.37M | -114.77M | -104.36M | -86.06M |
| NetInterestIncome | 12.64M | 9.91M | 3.12M | 120.00K |
| InterestIncome | 120.00K | |||
| NormalizedIncome | -88.98M | -104.70M | -101.07M | -85.81M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -88.98M | -104.70M | -101.07M | -85.81M |
| TotalExpenses | 137.93M | 123.55M | 116.76M | 86.06M |
| TotalOperatingIncomeAsReported | -101.37M | -114.77M | -104.36M | -86.06M |
| DilutedAverageShares | 54.01M | 43.99M | 38.90M | 36.74M |
| BasicAverageShares | 54.01M | 43.99M | 38.90M | 36.74M |
| DilutedEPS | -1.65 | -2.38 | -2.60 | -2.34 |
| BasicEPS | -1.65 | -2.38 | -2.60 | -2.34 |
| DilutedNIAvailtoComStockholders | -88.98M | -104.70M | -101.07M | -85.81M |
| NetIncomeCommonStockholders | -88.98M | -104.70M | -101.07M | -85.81M |
| NetIncome | -88.98M | -104.70M | -101.07M | -85.81M |
| NetIncomeIncludingNoncontrollingInterests | -88.98M | -104.70M | -101.07M | -85.81M |
| NetIncomeContinuousOperations | -88.98M | -104.70M | -101.07M | -85.81M |
| PretaxIncome | -88.98M | -104.70M | -101.07M | -85.81M |
| OtherIncomeExpense | -247.00K | 166.00K | 167.00K | 140.00K |
| OtherNonOperatingIncomeExpenses | -247.00K | 166.00K | 167.00K | 140.00K |
| NetNonOperatingInterestIncomeExpense | 12.64M | 9.91M | 3.12M | 120.00K |
| TotalOtherFinanceCost | -12.64M | -9.91M | -3.12M | -120.00K |
| InterestIncomeNonOperating | 120.00K | |||
| OperatingIncome | -101.37M | -114.77M | -104.36M | -86.06M |
| OperatingExpense | 137.93M | 123.55M | 116.76M | 86.06M |
| ResearchAndDevelopment | 89.13M | 82.23M | 77.84M | 54.17M |
| SellingGeneralAndAdministration | 48.79M | 41.32M | 38.92M | 31.90M |
| GeneralAndAdministrativeExpense | 48.79M | 41.32M | 38.92M | 31.90M |
| OtherGandA | 48.79M | 41.32M | 38.92M | 31.90M |
| TotalRevenue | 36.55M | 8.78M | 12.40M | 0.00 |
| OperatingRevenue | 36.55M | 8.78M | 12.40M | 0.00 |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 54.03M | 45.92M | 39.44M | 36.90M |
| ShareIssued | 54.03M | 45.92M | 39.44M | 36.90M |
| TotalDebt | 2.32M | 2.06M | 2.36M | 1.51M |
| TangibleBookValue | 229.02M | 159.56M | 184.85M | 217.78M |
| InvestedCapital | 229.02M | 159.56M | 184.85M | 217.78M |
| WorkingCapital | 192.70M | 184.52M | 212.68M | 212.08M |
| NetTangibleAssets | 229.02M | 159.56M | 184.85M | 217.78M |
| CapitalLeaseObligations | 2.32M | 2.06M | 2.36M | 1.51M |
| CommonStockEquity | 229.02M | 159.56M | 184.85M | 217.78M |
| TotalCapitalization | 229.02M | 159.56M | 184.85M | 217.78M |
| TotalEquityGrossMinorityInterest | 229.02M | 159.56M | 184.85M | 217.78M |
| StockholdersEquity | 229.02M | 159.56M | 184.85M | 217.78M |
| GainsLossesNotAffectingRetainedEarnings | -151.00K | -24.00K | -1.18M | -168.00K |
| OtherEquityAdjustments | -151.00K | -24.00K | -1.18M | -168.00K |
| RetainedEarnings | -490.83M | -401.85M | -297.15M | -196.08M |
| AdditionalPaidInCapital | 720.00M | 561.43M | 483.17M | 414.02M |
| CapitalStock | 5.00K | 5.00K | 4.00K | 4.00K |
| CommonStock | 5.00K | 5.00K | 4.00K | 4.00K |
| TotalLiabilitiesNetMinorityInterest | 42.53M | 68.78M | 71.22M | 21.09M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 2.48M | 37.96M | 39.82M | 3.95M |
| OtherNonCurrentLiabilities | 2.48M | 4.88M | 2.97M | 3.95M |
| NonCurrentDeferredLiabilities | 0.00 | 33.07M | 36.86M | 0.00 |
| NonCurrentDeferredRevenue | 0.00 | 33.07M | 36.86M | 0.00 |
| CurrentLiabilities | 40.06M | 30.82M | 31.39M | 17.14M |
| OtherCurrentLiabilities | 753.00K | 857.00K | 509.00K | 540.00K |
| CurrentDeferredLiabilities | 18.99M | 15.31M | 14.88M | 0.00 |
| CurrentDeferredRevenue | 18.99M | 15.31M | 14.88M | 0.00 |
| CurrentDebtAndCapitalLeaseObligation | 2.32M | 2.06M | 2.36M | 1.51M |
| CurrentCapitalLeaseObligation | 2.32M | 2.06M | 2.36M | 1.51M |
| PensionandOtherPostRetirementBenefitPlansCurrent | 7.69M | 5.61M | 5.75M | 5.38M |
| PayablesAndAccruedExpenses | 10.30M | 6.98M | 7.89M | 9.71M |
| CurrentAccruedExpenses | 7.81M | 5.29M | 7.13M | 7.32M |
| Payables | 2.50M | 1.70M | 766.00K | 2.38M |
| AccountsPayable | 2.50M | 1.70M | 766.00K | 2.38M |
| TotalAssets | 271.56M | 228.34M | 256.07M | 238.87M |
| TotalNonCurrentAssets | 38.80M | 13.00M | 12.00M | 9.65M |
| OtherNonCurrentAssets | 721.00K | 569.00K | 569.00K | 569.00K |
| InvestmentsAndAdvances | 29.82M | 0.00 | ||
| InvestmentinFinancialAssets | 29.82M | 0.00 | ||
| AvailableForSaleSecurities | 29.82M | |||
| NetPPE | 8.25M | 12.43M | 11.43M | 9.08M |
| AccumulatedDepreciation | -8.85M | -6.67M | -4.21M | -2.66M |
| GrossPPE | 17.10M | 19.11M | 15.63M | 11.74M |
| Leases | 2.33M | 2.29M | 1.87M | 263.00K |
| ConstructionInProgress | 120.00K | 65.00K | 447.00K | 1.61M |
| OtherProperties | 13.86M | 15.99M | 12.66M | 9.61M |
| MachineryFurnitureEquipment | 794.00K | 752.00K | 665.00K | 261.00K |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 232.76M | 215.34M | 244.07M | 229.22M |
| OtherCurrentAssets | 3.96M | 2.56M | 2.96M | 2.22M |
| CurrentDeferredAssets | 0.00 | 117.00K | ||
| RestrictedCash | 75.00K | 0.00 | ||
| PrepaidAssets | 11.12M | 11.32M | 10.93M | 6.94M |
| Receivables | 700.00K | 64.00K | 588.00K | 132.00K |
| AccruedInterestReceivable | 700.00K | 64.00K | 588.00K | 132.00K |
| CashCashEquivalentsAndShortTermInvestments | 216.90M | 201.39M | 229.59M | 219.81M |
| OtherShortTermInvestments | 88.92M | 9.95M | 116.04M | 74.92M |
| CashAndCashEquivalents | 127.98M | 191.44M | 113.56M | 144.90M |
| CashEquivalents | 191.44M | 113.56M | 144.90M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -87.05M | -82.68M | -35.83M | -68.11M |
| IssuanceOfCapitalStock | 128.84M | 52.08M | 45.34M | 0.00 |
| CapitalExpenditure | -203.00K | -1.62M | -3.96M | -1.20M |
| EndCashPosition | 128.78M | 192.01M | 114.12M | 145.46M |
| BeginningCashPosition | 192.01M | 114.12M | 145.46M | 287.51M |
| ChangesInCash | -63.23M | 77.89M | -31.34M | -142.05M |
| FinancingCashFlow | 131.09M | 53.01M | 46.41M | 1.28M |
| CashFlowFromContinuingFinancingActivities | 131.09M | 53.01M | 46.41M | 1.28M |
| NetOtherFinancingCharges | 1.00K | -2.00K | ||
| ProceedsFromStockOptionExercised | 2.25M | 926.00K | 1.06M | 1.29M |
| NetCommonStockIssuance | 128.84M | 52.08M | 45.34M | 0.00 |
| CommonStockIssuance | 128.84M | 52.08M | 45.34M | 0.00 |
| InvestingCashFlow | -107.47M | 105.95M | -45.88M | -76.43M |
| CashFlowFromContinuingInvestingActivities | -107.47M | 105.95M | -45.88M | -76.43M |
| NetInvestmentPurchaseAndSale | -107.27M | 107.56M | -41.92M | -75.23M |
| SaleOfInvestment | 60.00M | 107.56M | 159.40M | 12.00M |
| PurchaseOfInvestment | -167.27M | 0.00 | -201.32M | -87.23M |
| NetPPEPurchaseAndSale | -203.00K | -1.62M | -3.96M | -1.20M |
| PurchaseOfPPE | -203.00K | -1.62M | -3.96M | -1.20M |
| OperatingCashFlow | -86.85M | -81.07M | -31.87M | -66.91M |
| CashFlowFromContinuingOperatingActivities | -86.85M | -81.07M | -31.87M | -66.91M |
| ChangeInWorkingCapital | -28.14M | -6.03M | 43.02M | 46.00K |
| ChangeInOtherWorkingCapital | -29.39M | -3.35M | 51.74M | |
| ChangeInPayablesAndAccruedExpense | 3.09M | -3.21M | -3.53M | 2.90M |
| ChangeInPrepaidAssets | -1.84M | 529.00K | -5.18M | -2.85M |
| OtherNonCashItems | 2.27M | 2.26M | 1.99M | 1.26M |
| StockBasedCompensation | 27.47M | 25.26M | 22.85M | 16.45M |
| AmortizationOfSecurities | -1.64M | -325.00K | -211.00K | 143.00K |
| DepreciationAmortizationDepletion | 2.18M | 2.47M | 1.55M | 974.00K |
| DepreciationAndAmortization | 2.18M | 2.47M | 1.55M | 974.00K |
| Depreciation | 2.18M | 2.47M | 1.55M | 974.00K |
| OperatingGainsLosses | 1.00K | 29.00K | ||
| GainLossOnSaleOfPPE | 0.00 | 1.00K | 0.00 | 29.00K |
| NetIncomeFromContinuingOperations | -88.98M | -104.70M | -101.07M | -85.81M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for STOK
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|